Your browser doesn't support javascript.
loading
Combined proteomic and transcriptomic approaches reveal externalized keratin 8 as a potential therapeutic target involved in invasiveness of head and neck cancers.
Albaret, Marie Alexandra; Paré, Arnaud; Malet, Lucie; De Souza, Geneviève; Lavergne, Emilie; Goga, Dominique; De Pinieux, Gonzague; Castellier, Claire; Swalduz, Aurélie; Robin, Vivian; Lavergne, Vincent; Mertani, Hichem-Claude; Treilleux, Isabelle; Vermot-Desroches, Claudine; Diaz, Jean-Jacques; Saintigny, Pierre.
Afiliação
  • Albaret MA; Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, Centre Léon Bérard, Cancer Research Center of Lyon, 69008 Lyon, France; Department of Translational Research and Innovation, Centre Léon Bérard, 69373 Lyon, France.
  • Paré A; Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, Centre Léon Bérard, Cancer Research Center of Lyon, 69008 Lyon, France; Department of Translational Research and Innovation, Centre Léon Bérard, 69373 Lyon, France; Department of Maxillofacial and Plastic surgery, CHRU of Tours
  • Malet L; Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, Centre Léon Bérard, Cancer Research Center of Lyon, 69008 Lyon, France; Department of Translational Research and Innovation, Centre Léon Bérard, 69373 Lyon, France.
  • De Souza G; Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, Centre Léon Bérard, Cancer Research Center of Lyon, 69008 Lyon, France; Department of Translational Research and Innovation, Centre Léon Bérard, 69373 Lyon, France.
  • Lavergne E; Biostatistics Unit, Centre Léon Bérard, 69373 Lyon, France.
  • Goga D; Department of Maxillofacial and Plastic surgery, CHRU of Tours, 37170 Chambray-lés-Tours, France; University of François Rabelais, School of Medicine, Tours F-37032, France.
  • De Pinieux G; Department of Pathology, CHRU of Tours, 37170 Chambray-lés-Tours, France; University of François Rabelais, School of Medicine, Tours F-37032, France.
  • Castellier C; Department of Pathology, CHRU of Tours, 37170 Chambray-lés-Tours, France; University of François Rabelais, School of Medicine, Tours F-37032, France.
  • Swalduz A; Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, Centre Léon Bérard, Cancer Research Center of Lyon, 69008 Lyon, France; Department of Translational Research and Innovation, Centre Léon Bérard, 69373 Lyon, France; Department of Medicine, Centre Léon Bérard, 69373 Lyon, France
  • Robin V; Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, Centre Léon Bérard, Cancer Research Center of Lyon, 69008 Lyon, France; Department of Translational Research and Innovation, Centre Léon Bérard, 69373 Lyon, France.
  • Lavergne V; Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, Centre Léon Bérard, Cancer Research Center of Lyon, 69008 Lyon, France; Department of Translational Research and Innovation, Centre Léon Bérard, 69373 Lyon, France.
  • Mertani HC; Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, Centre Léon Bérard, Cancer Research Center of Lyon, 69008 Lyon, France.
  • Treilleux I; Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, Centre Léon Bérard, Cancer Research Center of Lyon, 69008 Lyon, France; Department of Translational Research and Innovation, Centre Léon Bérard, 69373 Lyon, France; Department of Pathology, Centre Léon Bérard, 69373 Lyon, Franc
  • Vermot-Desroches C; IDD BIOTECH, Bâtiment Accinov, 317 avenue Jean Jaurès, 69007, Lyon, France.
  • Diaz JJ; Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, Centre Léon Bérard, Cancer Research Center of Lyon, 69008 Lyon, France. Electronic address: jean-jacques.diaz@lyon.unicancer.fr.
  • Saintigny P; Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, Centre Léon Bérard, Cancer Research Center of Lyon, 69008 Lyon, France; Department of Translational Research and Innovation, Centre Léon Bérard, 69373 Lyon, France; Department of Medicine, Centre Léon Bérard, 69373 Lyon, France
Transl Oncol ; 14(1): 100878, 2021 Jan.
Article em En | MEDLINE | ID: mdl-33010552
ABSTRACT
Keratin 8 (K8) expressed at the surface of cancer cells, referred as externalized K8 (eK8), has been observed in a variety of carcinoma cell lines. K8 has been previously reported to be expressed in poorly differentiated head and neck squamous cell carcinoma (HNSCC); however, its role during the invasive phase of upper aerodigestive tract tumorigenesis is unknown. Cohorts of HNSCC tumors for protein and mRNA expression and panel of cell lines were used for investigation. K8 was found to be externalized in a majority of HNSCC cell lines. Among the two main K8 protein isoforms only the 54 kDa was found to be present at the plasma membrane of HNSCC cells. The plasminogen-induced invasion of HNSCC cells was inhibited by the anti-eK8 D-A10 antagonist monoclonal antibody. Overexpression of K8 mRNA and protein were both correlated with tumor aggressive features and poor outcome. The effect of eK8 neutralization on invasion, its presence exclusively in cancer cells and the association of K8 expression with aggressive features and poor clinical outcome in HNSCC unravel eK8 as key player in invasion and a promising therapeutic target in HNSCC.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article